Clinical Trial to Evaluate the Safety and Efficacy of JP-1366 in Patients With Erosive Gastroesophageal Reflux Disease

• Status: Recruiting
• Trial end date: 2020-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Clinical trial to evaluate the safety and efficacy of JP-1366 in patients with erosive gastroesophageal reflux disease

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Jeil Pharmaceutical Co., Ltd.
• Treatments: Esomeprazole

Criteria

Inclusion Criteria:

• Adults between 19 and 75 years old based on the date of written agreement

• Those who have been diagnosed with erosive gastroesophageal reflux disease(EGRD) of LA Grade A-D on the upper gastrointestinal endoscopy

• Those who experienced symptoms of heartburn or acid reflux within the last 7 days

Exclusion Criteria:

• Those who have undergone gastric acid suppression or gastric, esophageal surgery

• Those who with clinically significant liver, kidney, nervous system, respiratory, endocrine, hematologic, cardiovascular, urinary system disease

• Clinically significant abnormal laboratory values during screening